 |
Photo courtesy of Yonhap News |
[Alpha Biz= Paul Lee] Samsung Biologics (KRX: 207940) has acquired GlaxoSmithKline’s biopharmaceutical manufacturing facility in Rockville, Maryland, through its U.S. subsidiary, Samsung Biologics America, for USD 280 million. The acquisition, expected to complete in Q1 2026, marks the company’s first U.S.-based production site.
The facility, with a 60,000-liter drug substance capacity across two buildings, supports antibody production from clinical to commercial scale. The move eliminates the 15% U.S. tariff risk on pharmaceuticals and strengthens Samsung Biologics’ position for new contracts under the National Defense Authorization Act.
Existing contracts and approximately 500 employees at the facility will be retained. The company also announced three new European CMO agreements valued at KRW 1.223 trillion, increasing total 2025 orders to KRW 6.819 trillion, up 26.1% from 2024.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
